FDA CRL - Baxter Healthcare Corporation

The U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) to Baxter Healthcare Corporation regarding its New Drug Application (NDA 218408) for an unnamed chloride product. The application cannot be approved in its current form due to significant deficiencies. Key issues include unspecified problems related to product quality and inadequate submissions for both prescribing information and carton/container labeling, which require revisions to align with regulatory standards, including submission in Structured Product Labeling (SPL) format.

A major component of the CRL mandates a comprehensive safety update. Baxter must provide detailed new safety data from all clinical studies, incorporating it with original application data, presenting updated exposure information, and offering retabulations of adverse events and trial discontinuations. The company is also required to submit case report forms and narrative summaries for serious adverse events, deaths, or trial withdrawals, along with a summary of worldwide safety experience and English translations of foreign labeling.

Baxter must submit a complete response addressing all identified deficiencies within one year, clearly labeled as a "RESUBMISSION." The product cannot be legally marketed until it receives FDA approval. Baxter has the option to request a meeting with the FDA to discuss the necessary steps for approval.